Actinium Pharmaceuticals, Inc. (ATNM: NYSE MKT) is a publicly traded biopharmaceutical company developing innovative targeted payload immunotherapies for the treatment of advanced cancers. The Company's radioimmunotherapy product candidates are based on the combination of the cancer targeting precision of monoclonal antibodies (mAb) that seek out specific types of cells combined with the cytotoxic killing power of radioisotopes that unleash their energy once they have reached their target.

Iomab-B, licensed from Fred Hutchinson Cancer Research Center and Actinium's lead product, is in a single, pivotal Phase 3 clinical trial. Iomab-B is intended to be an induction and conditioning agent prior to a bone marrow transplant in relapsed or refractory Acute Myeloid Leukemia (AML) patients over the age of 55. Iomab-B is a myeloablative therapy, meaning it destroys a patient's bone marrow so that a patient can receive bone marrow from a donor via a transplant. Learn more about Iomab-B and bone marrow transplant for AML here.

Actimab-A, is Actinium's lead alpha-particle therapy that was licensed from Memorial Sloan Kettering Cancer Center. Actimab-A is intended to treat newly diagnosed AML patients over the age of 60 and is in a Phase 1/2 clinical trial at leading cancer centers in the United States. Actimab-A recently completed the Phase 1 portion of the clinical trial and will begin the Phase 2 portion of the trial with an optimized protocol this year. To learn more about Actimab-A visit this link.

Actinium Pharmaceuticals has a committed focus to its clinical programs but maintains research and development efforts based on its Alpha Particle Immunotherapy Platform (APIT). To learn more about Actinium's APIT or to explore a potential collaboration using this powerful technology please visit the Technology page.